title: Immunologic systemic effect of neoadjuvant chemotherapy requires investigation before tumor-associated lymphocytes can be introduced in breast cancer treatment algorithm.
authors.forename: Filippo
authors.initials: F
authors.lastname: Bellati
authors.forename: Chiara
authors.initials: C
authors.lastname: Napoletano
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Gasparri
authors.forename: Pierluigi Benedetti
authors.initials: PB
authors.lastname: Panici
authors.forename: Marianna
authors.initials: M
authors.lastname: Nuti
mesh_terms: D000465:Algorithms; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D020360:Neoadjuvant Therapy; D018579:Patient Selection; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D043823:Taxoids